What is the treatment for isoniazid-induced peripheral neuropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Isoniazid-Induced Peripheral Neuropathy

Pyridoxine (vitamin B6) supplementation is the primary treatment for isoniazid-induced peripheral neuropathy, with recommended doses of 50-100 mg daily until symptoms resolve. 1, 2

Pathophysiology and Mechanism

  • Isoniazid competitively inhibits the action of pyridoxine in metabolic functions, leading to deficiency in pyridoxal phosphate (the active form of vitamin B6), which is essential for nerve function 3
  • This deficiency causes axonal degeneration and disruption of nerve fibers, particularly affecting motor neurons that supply distal muscles 4
  • The neuropathy is dose-dependent and more common in slow acetylators of isoniazid 5

Clinical Presentation

  • Symptoms typically begin with numbness and paresthesia in the extremities 4
  • May progress to loss of distal sensation, motor ataxia, weakness, and loss of deep tendon reflexes 4, 6
  • Motor symptoms can be prominent, with significant weakness of lower limbs 6

Treatment Protocol

Immediate Management

  • Administer pyridoxine supplementation at doses of 50-100 mg daily 1, 2
  • Consider temporary discontinuation of isoniazid in severe cases 7, 6
  • If isoniazid must be continued (e.g., in drug-resistant TB), maintain pyridoxine supplementation at higher doses 6

Medication Options for Symptomatic Relief

  • For neuropathic pain, consider:
    • First-line: Duloxetine 30-60 mg daily 8, 9
    • Second-line: Pregabalin 150-600 mg daily or gabapentin 300-2,400 mg daily 10, 9
    • For persistent pain: Tramadol for chronic pain management 10, 9

Non-Pharmacological Interventions

  • Recommend wearing loose-fitting shoes and cotton socks 10
  • Encourage regular walking to help blood circulation in the feet 10
  • Suggest soaking feet in cold water and massage for temporary pain relief 10

Prevention Strategies

  • Prophylactic pyridoxine (10-25 mg daily) should be given to all patients on isoniazid who are at high risk of developing neuropathy 1, 11
  • High-risk groups include:
    • Patients with diabetes, uremia, alcoholism, or malnutrition 12, 1
    • HIV-positive individuals 1, 11
    • Pregnant women 12
    • Patients with seizure disorders 12
    • Malnourished individuals 7

Monitoring and Follow-up

  • Regular clinical assessment for symptoms of peripheral neuropathy in all patients on isoniazid therapy 1
  • More frequent monitoring for high-risk patients 12, 1
  • Assess for improvement in symptoms after initiating treatment 6

Prognosis

  • Most cases of isoniazid-induced peripheral neuropathy are reversible with appropriate pyridoxine supplementation 6, 5
  • Improvement typically begins within 2-3 weeks of starting pyridoxine treatment 7, 6
  • Some patients may have persistent mild sensory impairment even after treatment 6

Important Considerations and Pitfalls

  • Do not use excessive doses of pyridoxine (>200 mg daily) as this can itself cause peripheral neuropathy 4, 13
  • Patients with renal insufficiency or on low-protein diets are at higher risk of pyridoxine toxicity 10
  • High doses of vitamin C should be avoided as they may interfere with isoniazid metabolism 10
  • Even patients on standard isoniazid doses (5 mg/kg) can develop neuropathy if they have risk factors 7, 6
  • Peripheral neuropathy can occur even after months of well-tolerated isoniazid therapy 1, 6

References

Research

Isoniazid induced motor-dominant neuropathy.

JPMA. The Journal of the Pakistan Medical Association, 2015

Research

Isoniazid-induced neuropathy in a pre-pubertal child.

Paediatrics and international child health, 2019

Guideline

Reversible Causes of Peripheral Neuropathy and Their Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.